Cv Sciences Stock Price, News & Analysis

CV Sciences reported Q3 2024 financial results with revenue of $3.9 million, down 5% from Q3 2023's $4.1 million. Gross margin improved to 46.0% compared to 45.1% in Q3 2023. The company maintained a cash balance of $1.0 million and secured financing of $0.9 million from Streeterville. Notable developments include the launch of +PlusHLTH™, a cannabinoid-free supplement line, and expansion of pet product offerings. B2B sales declined 9% due to state CBD regulations. The company reported an operating loss of $0.3 million and negative adjusted EBITDA of $75,000, showing improvement from Q3 2023.

CV Sciences (OTCQB:CVSI), a consumer wellness company focused on hemp extracts and natural ingredients, has announced it will release its Q3 2024 financial results on November 14, 2024, before market open. The company will host a conference call with investors at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) on the same day. The webcast will be available on the company's Investor Relations website and archived for approximately 30 days. U.S. investors can join via (877) 407-0784, while international callers can use (201) 689-8560. A replay will be available until November 21, 2024.

CV Sciences (OTCQB: CVSI) has launched +PlusHLTH, a new line of cannabinoid-free supplements designed to enhance focus, mood, energy, and metabolism. The product line includes three variations:

1. Clarity: A cognitive enhancer with DMAE, Huperzine A, Rhodiola, and Lion's Mane.
2. Peace: A stress-relief formula with Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine.
3. ReShape: A metabolism and weight management supplement with Berberine, OEA, and Cinnamon.

The new products are available nationwide at select retailers and on the company's website. CEO Joseph Dowling stated that +PlusHLTH fills a growing demand for natural supplements addressing key wellness challenges, offering a cannabinoid-free alternative or complement to their CBD-based product line.

CV Sciences, Inc. (OTCQB:CVSI) reported its Q2 2024 financial results, showing stable revenue of $4.0 million, consistent with Q2 2023 and Q1 2024. The company achieved a gross margin of 47.0%, its best in 13 quarters, up from 43.3% in Q2 2023. CV Sciences maintained its position as the top-selling hemp extract brand in natural product retail sales. The company acquired Elevated Softgels and appointed Maxim Group as a financial advisor. Despite an operating loss of $0.6 million, this was an improvement from the $1.1 million loss in Q2 2023. CV Sciences reported negative adjusted EBITDA of $6,000, close to break-even, compared to $0.9 million in Q2 2023. The company's cash balance stood at $0.5 million at quarter-end, down from $1.3 million at the end of 2023.

CV Sciences (OTCQB: CVSI), a leading consumer wellness company specializing in hemp extracts and natural products, has announced its plans to release financial results for the second quarter of 2024 on Tuesday, August 13, 2024, before the stock market opens. The company will host a conference call with investors at 7:00 a.m. Pacific Time on the same day.

Investors can access the webcast through the company's Investor Relations website or directly via a provided link. For those preferring to participate by phone, U.S. callers can dial (877) 407-0784, while international callers should use (201) 689-8560. A replay of the call will be available until August 20, 2024.

CV Sciences (OTCQB: CVSI) announced its first quarter 2024 financial results.

The company generated $4.0 million in revenue, a 2.6% rise from the previous quarter but a 4% year-over-year decline. Its gross margin improved to 46.3% compared to 43.0% in Q1 2023 and 45.8% in Q4 2023. However, the cash balance dropped to $0.7 million from $1.3 million at the end of 2023. The company reported a $0.6 million operating loss, partly due to decreased B2B sales, although B2C sales rose by 3%. The acquisition of Elevated Softgels was highlighted as a strategic move for future growth. CV Sciences remains the top-selling hemp extract brand in natural product retail channels.

CV Sciences (OTCQB:CVSI) has acquired Elevated Softgels, a GMP-certified and FDA-registered manufacturer of encapsulated softgels and tinctures. Elevated Softgels' flexible production capabilities allow CV Sciences to in-source production of key products, potentially leading to significant cost savings. The acquisition involves a total consideration of up to $1,000,000, including a cash payment of $100,000, shares valued at $700,000, and up to $200,000 in performance-based earn-outs. Elevated Softgels, now a wholly-owned subsidiary, is expected to contribute to immediate growth and long-term shareholder value.

CV Sciences, Inc. will announce its first-quarter 2024 financial results on May 14, 2024. The company specializes in hemp extracts and natural products. The conference call with the investment community will take place at 7:00 a.m. Pacific Time on the same day. Interested investors can access the webcast on the Investor Relations section of the company's website, and a telephone replay will be available.